Phoenix Biotech Acquisition Corp.
closedU=S+W/2W=S@11.50
CERO
Capital Structure & Economics
Trust Size$158,100,000
Unit Price$2.00
Warrant Coverage1/2
Sponsor Promote20%
Implied Equity Architecture
Capital Allocation Baseline
Trust (100.0%)
Implied Dilution Drag
50% Warrant Inclusion| Public Trust Allocation | $158,100,000 |
| Sponsor At-Risk Capital | N/A |
| Total Underwriting Discount | N/A |
| Trust Per Unit (Implied) | $2.00 |
| Sponsor Promote Allocation | 20% |
Deal Lifecycle
IPO PricedSep 13, 2021
Target AnnouncedJun 4, 2023
Maturation Wall
N/A
Announced Target / M&A
- Target CompanyCERo
- SectorImmunotherapy
- Announcement Date2023-06-04
Board & Officers
- CEO
- Director
- Kristen PierceDirector
- Director
- Director
- Kathleen LaPorteDirector
- Lindsey Rolfe, M.D.Director
- Director
- Charles CarterDirector
- Brian AtwoodDirector
- Director
- Douglas FisherDirector
- Barbara KosaczDirector
- Caroline LoewyDirector
Advanced Structuring Terms
| Target Sectors | Immunotherapy |
Syndicate & Advisors
- LEAD
- FINANCIAL ADVISOR
Interactive Deal Modeling
Base financial constraints (Trust Size, Warrants, Promote) are pre-loaded into the calculation engines. Proceed to model implied dilution and advisory friction limits.